Navigation Links
Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth
Date:7/17/2013

NEW YORK, July 17, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth

http://www.reportlinker.com/p01555349/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-to-2019---Highly-Priced-New-Combination-Products-Forecast-to-Capture-Significant-Market-Share-and-Drive-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

 

Summary

 

 

GBI Research, a leading business intelligence provider, has released its latest research report "Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth". The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach a value of $15.6 billion by 2019. Much of this growth will be fuelled by a high number of new, more efficacious and convenient products entering the market and commanding greater value compared to the therapies already in the market. The drugs driving this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium.

 

Despite recent patent expirations, including that of Advair Diskus (salmeterol/fluticasone propionate), a market leader, generic erosion in the COPD market may not be as pronounced as that observed in other indications. This is largely down to the difficulty in replicating a fixed-dose combination therapy and the associated device. Indeed, since the US patent expired in 2010, Advair Diskus has faced little generic competition.

 

Although the COPD market is characterized by low diagnosis rates, campaigns to increase awareness of the disease in both patients and physicians has resulted in steadily rising diagnosis of COPD. Therefore, this has also contributed to market growth throughout the forecast period.

 

Scope

 

 

- A disease introduction, which defines the disease, including symptoms, diagnosis and treatment.

- An analysis of the COPD marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, displayed as a heat map.

- A detailed analysis of the COPD pipeline, detailing, among other parameters, drug distribution by phase, molecule type and mechanism of action. The COPD clinical trial landscape is then analysed, with a particular emphasis on failure rates across phases as well as the trends in clinical trial size and duration and by mechanism of action.

- An in-depth forecasting model for the COPD market, which considers the current marketed therapies, in addition to the potential market entry of new products. The model consists of a projected outcome, with high and low variance results, depending on the potential performance of pipeline therapies. This takes into account worst and best case scenarios for market uptake, costs and patent expirations.

- Strategic consolidations within the COPD indication are analyzed, which includes co-development and licensing agreements.

- An overview of the drivers and barriers for the COPD market is also included.

 

Reasons to buy

 

 

- Primarily, the report will allow clients to gain a strong understanding of the COPD indication, helping to identify and understand market opportunities and the emerging competitive environment. It will also allow you to:

- Understand the COPD pipeline and the factors which indicate that it is becoming more innovative as well as the key pipeline molecules that look set to have a big impact upon the COPD market.

- Observe detailed profiles for the promising pipeline products and gain insights into how they are likely to compete in the market, and what their main competitors will be.

- Follow the trends in COPD clinical trial size and duration in relation to industry averages. In addition, the report will enable you to assess the potential risk of future developmental programs for COPD therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates.

- Observe the potential growth patterns expected for the COPD market over the forecast period, and identify which countries are expected to contribute most to this growth.

 

 

 

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Disease Introduction 8

2.2 Symptoms 8

2.3 Etiology 8

2.4 Pathophysiology 9

2.5 Diagnosis 9

2.6 Assessment of Disease Severity 10

2.7 Treatment 10

2.7.1 Treatment Algorithm 12

3 Marketed Products 13

3.1 Product Profile 14

3.1.1 Spiriva – Boehringer Ingelheim Pharmaceuticals, Pfizer Inc. 14

3.1.2 Advair Diskus – GlaxoSmithKline 14

3.1.3 Symbicort – AstraZeneca (Co-promotion with Astellas Pharma Inc) 15

3.1.4 Combivent– Boehringer Ingelheim 16

3.1.5 Foradil – Novartis (Co-marketed by Novartis and Schering Corporation) 16

3.1.6 Arcapta/Onbrez Breezhaler – Novartis 17

3.1.7 Daliresp – Nycomed 18

3.1.8 Seebri Breezhaler – Novartis 19

3.1.9 Striverdi Respimat – Boehringer Ingelheim 19

3.1.10 Relvar/Breo – GlaxoSmithKline/Theravance 20

3.1.11 Heat Map – Marketed Products Overview 21

4 COPD Pipeline 23

4.1 Overview 23

4.2 Mechanisms of Action in the Pipeline 25

4.3 Clinical Trials 27

4.3.1 Failure Rate 27

4.3.2 Clinical Trial Duration 33

4.3.3 Clinical Trial Size 35

4.4 Promising Pipeline Molecules 38

4.4.1 Umeclidinium Bromide – GlaxoSmithKline 38

4.4.2 Umeclidinium Bromide + Vilanterol – GlaxoSmithKline/Theravance 38

4.4.3 Vilanterol Trifenatate – GlaxoSmithKline/Theravance 39

4.4.4 Olodaterol + tiotropium – Boehringer Ingelheim 39

4.4.5 TD-4208 – Theravance 40

4.4.6 QVA-149 – Novartis 40

4.4.7 Andolast (CR 2039) – Rottapharm | Madaus 41

4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products 41

5 Market Forecast to 2019 47

5.1 Geographical Markets 47

5.1.1 Global Market 49

5.1.2 United States 51

5.1.3 Top Five Countries of Europe 54

5.1.4 Japan 58

5.2 Drivers and Barriers for the COPD Market 60

5.2.1 Drivers 60

5.2.2 Barriers 61

6 Strategic Consolidations 62

6.1 Major Co-development Deals 62

6.1.1 Galapagos Enters into Strategic Alliance with Roche 63

6.1.2 Five Prime Therapeutics Enters into Co-development Agreement with GlaxoSmithKline 63

6.1.3 Forest Labs Enters into Co-development Agreement with Nycomed 63

6.2 Major Licensing Deals 64

6.2.1 Orexo Enters into Licensing Agreement with Ortho-McNeil-Janssen and Janssen Pharmaceutica 67

6.2.2 Mundipharma Enters into Licensing Agreement with SkyePharma 68

6.2.3 Evotec Enters into Licensing Agreement with Zhejiang Conba Pharma for EVT 401 68

6.2.4 Halozyme Therapeutics Enters into Licensing Agreement with Intrexon 68

7 Appendix 69

7.1 All Pipeline Drugs by Phase 69

7.1.1 Discovery 69

7.1.2 Pre-clinical 70

7.1.3 Phase I 73

7.1.4 Phase II 74

7.1.5 Phase III 75

7.1.6 Filed 75

7.1.7 Undisclosed 76

7.1.8 Market Forecasts to 2019 76

7.1.9 The United States 76

7.1.10 The UK 77

7.1.11 France 77

7.1.12 Germany 77

7.1.13 Italy 78

7.1.14 Spain 78

7.1.15 Japan 78

7.2 Market Definition 79

7.3 Abbreviations 79

7.4 References 80

7.4.1 References for Pipeline Heat Map 85

7.4.2 References for Marketed Products Heat Map 86

7.5 Methodology 86

7.6 Coverage 87

7.7 Secondary Research 87

7.8 Therapeutic Landscape 87

7.9 Epidemiology-Based Forecasting 88

7.10 Market Size by Geography 89

7.11 Geographical Landscape 90

7.12 Pipeline Analysis 90

7.13 Competitive Landscape 90

7.13.1 Expert Panel Validation 90

7.14 Contact Us 90

7.15 Disclaimer 90

 

1.1 List of Tables

 

Table 1: COPD Market, Introduction, Disease Severity, 2012 10

Table 2: COPD Market, Introduction, Treatment Algorithm, 2012 12

Table 3: COPD Market, Global, Pipeline, Discovery, 2013 69

Table 4: COPD Market, Global, Pipeline, Pre-clinical, 2013 70

Table 5: COPD Market, Global, Pipeline, Phase I, 2013 73

Table 6: COPD Market, Global, Pipeline, Phase II, 2013 74

Table 7: COPD Market, Global, Pipeline, Phase III, 2013 75

Table 8: COPD Market, Global, Pipeline, Filed, 2013 75

Table 9: COPD Market, Global, Pipeline, Undisclosed, 2013 76

Table 10: COPD, Global, Market Forecast, 2012–2019 76

Table 11: COPD, US, Market Forecast, 2012–2019 76

Table 12: COPD, UK, Market Forecast, 2012–2019 77

Table 13: COPD, France, Market Forecast, 2012–2019 77

Table 14: COPD, Germany, Market Forecast, 2012–2019 77

Table 15: COPD, Italy, Market Forecast, 2012–2019 78

Table 16: COPD, Spain, Market Forecast, 2012–2019 78

Table 17: COPD, Japan, Market Forecast, 2012–2019 78

 

1.2 List of Figures

 

Figure 1: COPD Market, Global, Marketed Products, Heat Map, 2012 21

Figure 2: COPD Market, Global, Pipeline, 2012 24

Figure 3: COPD Market, Global, Pipeline by Mechanism of Action, 2012 25

Figure 4: COPD Market, Global, Clinical Trials, Failure Rate, 2012 28

Figure 5: COPD Market, Global, Clinical Trials, Failure Rates by 30

Figure 6: COPD Market, Global, Pipeline, Failure Rates by Mechanism of Action, Heat Map, 2012 31

Figure 7: COPD Market, Global, Pipeline, Clinical Trial Duration, 2012 33

Figure 8: COPD Market, Global, Pipeline, Clinical Trial Duration by Mechanism, 2012 34

Figure 9: COPD Market, Global, Pipeline, Clinical Trial Size, 2012 35

Figure 10: COPD Market, Global, Pipeline, Clinical Trial Size by Mechanism of Action, 2012 36

Figure 11: COPD Market, Global, Pipeline, Number of Clinical Trials per Drug, 2012 37

Figure 12: COPD Market, Global, Pipeline, Efficacy Heat Map, 2012 42

Figure 13: COPD Market, Global, Pipeline, Safety Heat Map, 2012 43

Figure 14: COPD Market, Global, Marketed Products, Heat Map, 2012 44

Figure 15: COPD Market, Global, Pipeline, Competitor Grid, 2012 46

Figure 16: COPD Market, Global, Treatment Patterns, 2012–2019 49

Figure 17: COPD Market, Global, Market Size ($m) 2012–2019 50

Figure 18: COPD Market, the US, Treatment Usage Patterns, Annual Cost of Treatment ($), 2012–2019 51

Figure 19: COPD Market, US, Market Size ($m), 2012–2019 52

Figure 20: COPD Market, Top Five EU Countries, Treatment Usage Patterns, 2012–2019 54

Figure 21: COPD Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019 55

Figure 22: COPD Market, Top Five EU Countries, Market Size ($m), 2012–2019 57

Figure 23: COPD Market, Japan, Treatment Usage Patterns, Annual Cost of Treatment ($), 2012–2019 58

Figure 24: COPD Market, Japan, Market Size ($m), 2012–2019 59

Figure 25: COPD Market, Global, Co-development Deals, 2006–2012 62

Figure 26: COPD Market, Global, Number and Aggregate Value of Co-development Deals by Year, 2006–2013 63

Figure 27: COPD Market, Global, Licensing Deals, 2006–2012 64

Figure 28: COPD Market, Global, Number and Aggregate Value of Licensing Deals by Year, 2006–2012 64

Figure 29: COPD Market, Global, Licensing Deals, 2006–2012 65

Figure 30: COPD Market, Global, Licensing Deals by Phase and Molecule Type and Aggregate Deal Value, 2006–2012 66

Figure 31: COPD Market, Global, Licensing Deals by Mechanism of Action, 2006–2012 67

Figure 32: COPD Market, Global, GBI Research Market Sizing Model 89

 

 

 

To order this report:

Drug_Discovery_and_Development Industry: Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth

 

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
2. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
3. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
4. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
5. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
6. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
7. Hearing Loss Could Lead to Multiple Chronic Diseases for Millions of Brits
8. Remote Patient Monitoring Devices Market to 2017 - Chronic Disease Prevalence and Government Curbs on Hospital Spending to Drive the Market
9. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
10. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
11. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
Breaking Medicine News(10 mins):